Effectiveness of treatment of a patient for the first time diagnosed pulmonary tuberculosis with concomitant pathology depending on the method of administration of antimycobacterial drugs
Abstract
Resume. The use of antimycobacterial therapy in its majority leads to a positive dynamics of the TB disease, smear and sputum cultures conversion and cure of the patient. The lack of an expected positive response to the therapy happens in a limited number of patients. One of the most common reason for the lack of a positive response, in the conditions of the appointment of therapeutic agents in accordance with the identified sensitivity and controlled use of chemotherapy, may be the presence of concomitant pathology and malabsorption / maldigestia syndrome.
Your attention is given to the clinical case of the progression of pulmonary tuberculosis on the background of oral administration of antimycobacterial drugs. During the treatment, the presence of chronic pancreatitis and malabsorption syndrome of oral forms of drugs was confirmed, which allowed changing the treatment tactics and reaching the patient's cure.
References
Lienhardt, C. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes [Text] / C. Lienhardt, A. Vernon, M. C. Raviglione // Curr. Opin. Pulm. Med. – 2010. – Vol. 61. – № 3. – Р. 186–193.
Owens, S. R The pathology of malabsorption: current concepts. [Text] / S. R. Owens, J. K. Greenson // Histopathology. – 2007. – № 50 (1) : Р. 64 – 82.
Othman, M. Alterations in intestinal microbial flora and human disease [Text] // M. Othman, R. Agüero, H. Lin // January 2008. – Vol. 24. – Р. 11–16.
V. I. Chukanov. Scientific works dedicated to the 75th anniversary of the leading anti-tuberculosis institution in Moscow. M. - 2001. - P. 117 - 122.
Rattan, A. Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives [Text] / A. Rattan, A. Kalia, N. Ahmad // Emerging Infectious Diseases. – 1998. – Vol. 4. – № 2. – P. 195 – 209.
Sterling, T. R. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis [Text] / T. R. Sterling, H. P. Lehmann, T. R. Frieden // BMJ. – 2003. – Vol. 15. – P. 326 – 574.
Musser, J. M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights [Text] / J. M. Musser // Curr. Opin. Immunol. 1995. – Vol.8. – P. 496 - 514.
Nuermberger, E. Pharmacokinetic and pharmacodynamic issues in treatment of Mycobacterium infection [Text] / E. Nuermberger, J. Grosset // Eur. J. Clin. Microbiol. Infect. Dis. – 2004. – Vol. 23. – № 4. – P. 243–255.
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin [Text] / T. Gumbo [et al.] // Antimicrob. Agents Chemother. – 2007. – Vol. 51. – Р. 3781–3788.
Efferent therapy in the treatment of pulmonary tuberculosis patients with drug-resistant mycobacteria [Text] / NL Karpina [et al.] // Tuberculosis and lung disease. - 2010. - Vol. 3. - P. 28 - 33.
The effectiveness of treatment of patients with destructive pulmonary tuberculosis with parenteral and oral administration of anti-tuberculosis drugs [Text] / V. Yu. Mishin [et al.] // Pulmonology. - 2011. - Issue. 1. - P. 55–59 ; Boff, D. F.
Initial combination of injectable and oral anti-tuberculosis agents for the treatment of severe disseminated tuberculosis [Text] / D. F. Boff, L. Z. Goldani // Trop. Doct. – 2013. – Vol. 43. – № 4. – Р. 381–401.
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
